High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Moderna (NASDAQ:MRNA) shares rose 2. 9% in pre-market trading, recovering some ground after several sessions of declines that followed a dramatic rally triggered by positive Phase 3 results for its personalised mRNA cancer vaccine, intismeran autogene.
A number of stocks fell in the afternoon session after shares across biotech and big pharma cooled further as traders continued to secure profits following the extraordinary run. The sector had jumped after Phase 3 results for Moderna’s individualized neoantigen mRNA therapy, intismeran, used with Merck’s Keytruda — the first positive late-stage readout for an mRNA-based cancer vaccine over Keytruda alone. With no fresh clinical or regulatory catalyst to extend the advance, the tape has shifted
The European Commission on Monday authorized Trodelvy combined with Merck’s (MRK) Keytruda for certain adults with previously untreated advanced or metastatic triple-negative breast cancer.
Before the melanoma result, the visible signs were an enrolled trial, a partner paying half its cost, and a market that had stopped pricing an unusually large move.
The biotech fund is one of two ETFs in IBD Leaderboard. The S&P 500 Biotech index gapped up to nearly an all-time high last Wednesday, a bullish day for the industry. While Moderna shares have remained volatile since then — down 23.5% Thursday after rising 177% Wednesday — the biotech ETF is doing its job as a diversified fund, keeping its one-day price moves to within 6%.
While traders pointed to external clinical-trial momentum as a major catalyst, Tempus's own recent guidance raise and narrowing losses provided the underlying backdrop.
MRNA's cancer therapy scores a phase III win, strengthening its mRNA platform, while pipeline risks and competition remain key concerns.
Eli Lilly just crossed a $1 trillion market cap for the first time, and management is already pointing toward a milestone that would rewrite the drugmaker's history. Whether three converging pipeline catalysts can justify the valuation is the question every investor needs to answer now.
Moderna just handed back 7% of its staggering year-to-date run in a single session, and the question rattling traders is whether this is a routine exhale or the beginning of a painful unwind for latecomers.
Pfizer shares sit near a 52-week high after years of post-pandemic punishment, and now Wall Street analysts are quietly shifting their tone. Here is what the pipeline, the dividend, and the valuation math actually say about where PFE goes from here.
FEATURE Top executives at Moderna have been projecting high confidence in the commercial future of the company’s personalized cancer vaccine even as Wall Street holds out for complete trial results. The market reacted instantly to the initial readout.
Merck added billions in a single day after its Moderna-partnered cancer vaccine cleared a major hurdle.
Eyes are now on intismeran’s upcoming Phase II RCC readout, which they say could signal the drug’s wider potential across the solid tumour space.
Target, Merck, and Charles Schwab stocks surged to annual highs on Friday last week as positive company catalysts and Wall Street price target hikes bolstered prices higher.
Merck (NYSE: MRK) disclosed an equity stake in Evaxion A/S tied to an AI powered vaccine program centered on candidate EVX-B3. The company in licensed EVX-B3, an AI guided vaccine candidate, as part of its push into AI driven vaccine discovery. The move extends Merck's use of artificial intelligence beyond its existing focus on traditional pharmaceuticals and mRNA oncology research. Readers who want more ideas at the intersection of healthcare and artificial intelligence may also want to...
Moderna has always been a stock driven by narrative extremes. During the pandemic, it traded as if mRNA would transform medicine overnight, with its market capitalization peaking near $200 billion. Shares exploded 177% in a single session on Wednesday—the largest one-day surge for an S&P 500 company in over two decades—after Moderna and partner Merck reported successful late-stage trial results for their personalized mRNA melanoma vaccine.
Moderna Inc. (NASDAQ:MRNA) saw its share price more than double week-on-week to hit a new record high after reporting stellar results from the clinical trial of its melanoma therapy candidate in partnership with Merck. During the week, the stock climbed by as much as 179 percent to touch a record high of $176.66, before paring […]
Moderna's mRNA cancer vaccine breakthrough with Merck fueled a biotech rally, with the IBB near highs. Eli Lilly and Natera both show strong uptrends and possible breakouts.
ARCT stock was most recently buoyed by positive late-stage results from Merck and Moderna on their personalized mRNA cancer vaccine combined with Keytruda in high-risk melanoma patients.
Moderna's 130% day ran on five conditions. We screened the market for stocks like Moderna and found three names, none a biotech.
Scientists are on the cusp of fulfilling a decades-long quest: to use vaccines to teach the immune system to spot and destroy cancer cells. News that an mRNA cancer vaccine developed by Merck & Co. and Moderna Inc. kept melanoma from returning in a large, late-stage trial marks a critical next chapter for a technology beleaguered by post-pandemic political backlash and years of false starts before then. Bloomberg Opinion Columnist Lisa Jarvis writes "Moderna and Merck's Cancer Vaccine Is a Marvel."
The stock has gained over 20% in the past five days, marking its best week since early July.
The stock market still looks basically healthy, but the bond market is starting to show signs of stress.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
